CPI 1205

Drug Profile

CPI 1205

Alternative Names: CPI1205

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Constellation Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer; Prostate cancer
  • Phase I B cell lymphoma
  • Preclinical Multiple myeloma

Most Recent Events

  • 16 Jan 2018 Phase I/II clinical trials in Cancer (Combination therapy) (unspecified route)
  • 12 Dec 2017 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Combination therapy, Hormone refractory) in USA (unspecified route)
  • 03 Dec 2016 Preclinical trials in Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top